RU2666990C2 - Антитела к jagged и способы их применения - Google Patents

Антитела к jagged и способы их применения Download PDF

Info

Publication number
RU2666990C2
RU2666990C2 RU2015108797A RU2015108797A RU2666990C2 RU 2666990 C2 RU2666990 C2 RU 2666990C2 RU 2015108797 A RU2015108797 A RU 2015108797A RU 2015108797 A RU2015108797 A RU 2015108797A RU 2666990 C2 RU2666990 C2 RU 2666990C2
Authority
RU
Russia
Prior art keywords
antibody
seq
amino acid
acid sequence
hvr
Prior art date
Application number
RU2015108797A
Other languages
English (en)
Russian (ru)
Other versions
RU2015108797A (ru
Inventor
Кристиан В. СИБЕЛ
Янь Ву
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2015108797A publication Critical patent/RU2015108797A/ru
Application granted granted Critical
Publication of RU2666990C2 publication Critical patent/RU2666990C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2015108797A 2012-08-13 2013-08-13 Антитела к jagged и способы их применения RU2666990C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261682640P 2012-08-13 2012-08-13
US61/682,640 2012-08-13
US201361784332P 2013-03-14 2013-03-14
US61/784,332 2013-03-14
PCT/US2013/054664 WO2014028446A1 (en) 2012-08-13 2013-08-13 Anti-jagged anitbodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018130986A Division RU2018130986A (ru) 2012-08-13 2013-08-13 Антитела к jagged и способы их применения

Publications (2)

Publication Number Publication Date
RU2015108797A RU2015108797A (ru) 2016-10-10
RU2666990C2 true RU2666990C2 (ru) 2018-09-13

Family

ID=49004047

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015108797A RU2666990C2 (ru) 2012-08-13 2013-08-13 Антитела к jagged и способы их применения
RU2018130986A RU2018130986A (ru) 2012-08-13 2013-08-13 Антитела к jagged и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2018130986A RU2018130986A (ru) 2012-08-13 2013-08-13 Антитела к jagged и способы их применения

Country Status (10)

Country Link
US (4) US10113002B2 (enExample)
EP (1) EP2882776B1 (enExample)
JP (4) JP6352264B2 (enExample)
KR (2) KR102193080B1 (enExample)
CN (1) CN104520328B (enExample)
BR (1) BR112015003032B1 (enExample)
CA (1) CA2880271C (enExample)
MX (2) MX357675B (enExample)
RU (2) RU2666990C2 (enExample)
WO (1) WO2014028446A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
AU2013278075B2 (en) 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
WO2014028446A1 (en) 2012-08-13 2014-02-20 Genentech, Inc. Anti-jagged anitbodies and methods of use
US10350216B2 (en) * 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CA2902765A1 (en) * 2013-03-15 2014-09-25 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
HRP20181359T1 (hr) 2014-02-12 2018-10-19 F. Hoffmann - La Roche Ag Anti-jagged1 protutijela i postupci uporabe
US9914774B2 (en) 2014-07-11 2018-03-13 Genentech, Inc. Notch pathway inhibition
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060093599A1 (en) * 2004-11-03 2006-05-04 Gadi Gazit-Bornstein Anti-properdin antibodies, and methods for making and using same
US20070141065A1 (en) * 2003-08-01 2007-06-21 Genentech, Inc. Anti-VEGF antibodies
WO2008091641A2 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2011063237A2 (en) * 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20030170636A1 (en) 2002-03-05 2003-09-11 Isis Pharmaceuticals Inc. Antisense modulation of jagged 2 expression
US20030185829A1 (en) 2002-03-12 2003-10-02 Erich Koller Jagged 2 inhibitors for inducing apoptosis
US20040101847A1 (en) 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
WO2004019921A2 (en) 2002-08-29 2004-03-11 University Of Southampton Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
UA90082C2 (ru) 2002-11-15 2010-04-12 Дженмаб А/С Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
CA2508375C (en) 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
WO2005054434A2 (en) * 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
SI1771482T1 (sl) 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
AT502055B1 (de) 2005-06-21 2007-11-15 Univ Wien Med Anti tumor medikament
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
NZ577274A (en) 2006-12-18 2012-10-26 Genentech Inc Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
EP2155249A4 (en) * 2007-05-15 2011-11-16 Oncomed Pharm Inc COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
ES2517872T3 (es) 2007-08-10 2014-11-04 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos de alta afinidad para el factor de crecimiento nervioso humano
JP2009078998A (ja) 2007-09-26 2009-04-16 Univ Of Tokushima Ｊａｇｇｅｄ２を用いる制癌剤
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
JP5560270B2 (ja) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
JP5710487B2 (ja) 2008-10-01 2015-04-30 ジェネンテック， インコーポレイテッド 抗ｎｏｔｃｈ２抗体および使用方法
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
AU2013278075B2 (en) 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
WO2014028446A1 (en) 2012-08-13 2014-02-20 Genentech, Inc. Anti-jagged anitbodies and methods of use
CA2902765A1 (en) 2013-03-15 2014-09-25 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
HRP20181359T1 (hr) 2014-02-12 2018-10-19 F. Hoffmann - La Roche Ag Anti-jagged1 protutijela i postupci uporabe
US9914774B2 (en) * 2014-07-11 2018-03-13 Genentech, Inc. Notch pathway inhibition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141065A1 (en) * 2003-08-01 2007-06-21 Genentech, Inc. Anti-VEGF antibodies
US20060093599A1 (en) * 2004-11-03 2006-05-04 Gadi Gazit-Bornstein Anti-properdin antibodies, and methods for making and using same
WO2008091641A2 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2011063237A2 (en) * 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ВАРТАНЯН А. А. и др., Блокирование Notch сигнального пути стабилизирует васкулогенную мимикрию при меланоме, Российский биотерапевтический журнал, 2012, Т. 11. *

Also Published As

Publication number Publication date
RU2018130986A (ru) 2018-10-09
JP7366700B2 (ja) 2023-10-23
EP2882776B1 (en) 2018-05-02
RU2015108797A (ru) 2016-10-10
JP2015530989A (ja) 2015-10-29
US20190135936A1 (en) 2019-05-09
BR112015003032A2 (pt) 2017-12-12
MX381841B (es) 2025-03-13
RU2018130986A3 (enExample) 2021-12-22
MX357675B (es) 2018-07-18
CN104520328A (zh) 2015-04-15
JP2021191275A (ja) 2021-12-16
US20150232568A1 (en) 2015-08-20
HK1209432A1 (en) 2016-04-01
KR102193080B1 (ko) 2020-12-18
JP6352264B2 (ja) 2018-07-04
CA2880271A1 (en) 2014-02-20
CN104520328B (zh) 2019-06-07
BR112015003032A8 (pt) 2018-04-10
KR20200143502A (ko) 2020-12-23
JP6619047B2 (ja) 2019-12-11
EP2882776A1 (en) 2015-06-17
KR20150041656A (ko) 2015-04-16
US20200377610A1 (en) 2020-12-03
MX2015001942A (es) 2015-08-14
JP2018139595A (ja) 2018-09-13
JP2020048563A (ja) 2020-04-02
CA2880271C (en) 2021-10-19
US10113002B2 (en) 2018-10-30
US20240034805A1 (en) 2024-02-01
US10689455B2 (en) 2020-06-23
WO2014028446A1 (en) 2014-02-20
BR112015003032B1 (pt) 2023-03-28
US11702479B2 (en) 2023-07-18

Similar Documents

Publication Publication Date Title
US11746160B2 (en) Antibodies against BACE1 and use thereof for neural disease immunotherapy
KR102030891B1 (ko) 항-재기드1 항체 및 사용 방법
US10035854B2 (en) Method of treating retinopathy with an anti-LRP5 antibody
US20240034805A1 (en) Anti-Jagged Antibodies and Methods of Use
CN103261230A (zh) 抗pcsk9抗体及使用方法
WO2018186322A1 (en) Anti-masp-1 antibodies and methods of use
HK1209432B (zh) 抗锯齿蛋白抗体及使用方法